Recent developments highlight MAIA's clinical progress in Phase 2 and Phase 3 trials of ateganosine for NSCLC, regulatory clearances, funding milestones, and expanded trial enrollment internationally.

• MAIA reported increased disease control rate from Phase 2 THIO-101 trial for ateganosine in lung cancer [N1].
• The company completed international enrollment in Phase 2 THIO-101 Part C for ateganosine in lung cancer [N2].
• MAIA activated a second U.S. testing site in the Phase 2 THIO-101 trial for ateganosine in treating lung cancer [N3].
• MAIA advanced the Phase 3 THIO-104 trial of ateganosine in NSCLC, targeting enrollment of 100 patients by year-end 2026 [N4].
• The FDA granted clearance to expand the Phase 2 THIO-101 lung cancer trial in the U.S. [N5].
• MAIA secured $33 million in funding to support the Phase 3 trial [N6].
• The Phase 2 trial showed eight lung cancer patients surpassing two years of survival [N8].

MAIA's lead candidate, ateganosine, has demonstrated encouraging clinical efficacy signals in Phase 2 trials for advanced NSCLC, including high disease control rates and survival benefits in patients resistant to existing therapies. The initiation of a pivotal Phase 3 trial and FDA Fast Track designation provide regulatory incentives and pathways that could facilitate development progress. Collaborations with Regeneron and BeOne Medicines enable access to checkpoint inhibitors and broaden potential indications. The company's patent portfolio and ongoing development of second-generation compounds may strengthen its intellectual property position. Successful clinical outcomes and regulatory milestones could enhance MAIA's position in the immuno-oncology space.

MAIA remains a clinical-stage company with no approved products or revenue, incurring ongoing net losses and relying on external funding to support operations. The absence of cash and cash equivalents as of June 30, 2026, highlights liquidity constraints despite a positive current ratio. Clinical development risks include potential failure to demonstrate efficacy or safety in ongoing trials, regulatory uncertainties, and competition from established and emerging therapies. Dependence on third-party manufacturers and collaborators introduces operational risks. Intellectual property challenges and market acceptance remain uncertain. Any delays or setbacks in clinical trials or regulatory processes could materially impact the company's prospects.

MAIA's competitive advantages include its proprietary telomere-targeting technology platform centered on ateganosine, supported by a portfolio of patents granted and pending in multiple jurisdictions. The company has established collaborations with major industry players such as Regeneron and BeOne Medicines, providing access to checkpoint inhibitors for combination therapies at no cost, which reduces development expenses and enhances clinical trial capabilities. The FDA Fast Track designation for ateganosine facilitates regulatory engagement and potential expedited review pathways. MAIA's clinical data demonstrating promising efficacy and survival benefits in heavily pretreated NSCLC patients further supports its differentiation. However, as a clinical-stage company without commercial products, its moat depends on successful clinical development, regulatory approvals, and eventual commercialization.

• Clinical Development Risk: The success of MAIA depends on the outcomes of ongoing and future clinical trials of ateganosine. Failure to demonstrate safety and efficacy could delay or prevent regulatory approval.
• Regulatory Risk: Regulatory approvals are uncertain and may require additional data or changes to trial design. Accelerated or Fast Track designations do not guarantee approval or expedited review.
• Financial Risk: The company reported no cash and cash equivalents as of June 30, 2026, and continues to incur net losses, indicating reliance on external financing to fund operations and clinical development.
• Manufacturing and Supply Risk: MAIA relies on third-party contract manufacturers for production of clinical trial materials, which may pose risks related to quality, supply continuity, and regulatory compliance.
• Competition Risk: The biotechnology and oncology markets are highly competitive with many companies developing immunotherapies and targeted agents, which may limit market opportunities.

• MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, headquartered in Chicago, Illinois, with subsidiaries in Australia and Romania [S1].
• The lead product candidate is ateganosine (THIO), a telomere-targeting agent with a dual mechanism of action involving telomere targeting and immunogenicity, currently in clinical development for non-small cell lung cancer (NSCLC) [S1].
• Ateganosine is being developed primarily as a second- or later-line treatment for NSCLC patients who have progressed beyond standard-of-care regimens including checkpoint inhibitors [S1].
• The company has ongoing clinical trials: Phase 2 THIO-101 trial evaluating ateganosine in combination with Regeneron's checkpoint inhibitor cemiplimab (Libtayo®) and as monotherapy in NSCLC, including an expansion arm for third-line patients resistant to checkpoint inhibitors and chemotherapy [S1].
• A Phase 3 pivotal trial (THIO-104) was initiated in 2025 to evaluate ateganosine administered in sequence with a checkpoint inhibitor in third-line NSCLC patients, with up to 300 patients randomized 1:1 against chemotherapy [S1].
• Phase 2 clinical trials for hepatocellular carcinoma (HCC), colorectal cancer (CRC), and small cell lung cancer (SCLC) are planned for 2026, evaluating ateganosine with BeOne Medicines' immune checkpoint inhibitor tislelizumab [S1].
• MAIA has a clinical supply agreement with Regeneron to receive cemiplimab at no cost, granting Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC during the study period [S1].
• The FDA granted Fast Track designation for ateganosine in July 2025 for treatment of NSCLC, and the company intends to utilize expedited programs for development and review [S1].
• The company has reported positive clinical data from the THIO-101 Phase 2 trial, including high disease control rates (DCR), overall response rates (ORR), and survival benefits in heavily pretreated NSCLC patients [N1][N8][S1].
• Recent news reports indicate completion of international enrollment in Phase 2 THIO-101 Part C, activation of a second U.S. testing site, FDA clearance to expand the Phase 2 trial in the U.S., and advancement of the Phase 3 THIO-104 trial targeting 100 patients by year-end 2026 [N2][N3][N4][N5].
• MAIA secured $33 million in funding to support the Phase 3 trial [N6].
• The company reported eight lung cancer patients surpassing two years of survival in the Phase 2 trial [N8].
• As of June 30, 2026, MAIA had $0 in cash and cash equivalents, current assets of approximately $28.2 million, current liabilities of about $6.3 million, and a current ratio of 4.51, indicating liquidity coverage of current obligations [S2].
• The company reported a net loss of approximately $7.9 million and basic and diluted EPS of -$0.13 for the quarter ended June 30, 2026 [S2].
• MAIA does not own manufacturing facilities and relies on third-party contract manufacturers compliant with FDA cGMP regulations [S1].
• The company holds patents and patent applications covering ateganosine and related compounds in multiple jurisdictions, including a European patent granted in 2025 and several pending PCT applications [S1].
• MAIA maintains collaborations with Regeneron and BeOne Medicines for clinical supply and combination therapy trials [S1].
• The company has a small workforce of 13 full-time employees as of December 31, 2025, with operations primarily in Chicago and some remote team members [S1].